PALO ALTO, Calif., Sept. 17 Telik, Inc.(Nasdaq: TELK) announced that company management will provide a corporateoverview at the UBS Global Life Sciences Conference in New York City onWednesday, September 24, 2008 at 9:30 a.m. Eastern time (6:30 a.m. Pacifictime). Telik's presentation will be webcast live and will be available forreplay through the Telik website, http://www.telik.com, through October 25,2008.
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused ondiscovering, developing and commercializing novel small molecule drugs totreat serious diseases. The company's most advanced investigational drugcandidates in clinical development are TELINTRA(R), a modified glutathioneanalog for the treatment of cytopenias due to myelodysplastic syndrome orchemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment ofadvanced ovarian cancer and non-small cell lung cancer. Telik's productcandidates were discovered using its proprietary drug discovery technology,TRAP(R), which enables the rapid and efficient discovery of small moleculedrug candidates.
TELIK, the Telik logo, TELINTRA, TELCYTA, and TRAP are trademarks orregistered trademarks of Telik, Inc.
SOURCE Telik, Inc.